|Awarded On||February 21, 2018|
|Title||Myeloid support of refractory and aggressive T-ALL at distinct tumor sites|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas at Austin|
|Principal Investigator/Program Director||Lauren Ehrlich|
|Cancer Sites||Leukemia, Lymphoma|
Acute lymphoblastic leukemia (ALL) is the most common childhood malignancy, with the T cell subtype (T-ALL) representing ~15% of pediatric ALL cases. Current chemotherapeutic regimens have improved five-year event-free survival rates to ~80% in children. However, these therapies are toxic, often resulting in life-long morbidities. Furthermore, prognosis is dismal for ~20% of patients who relapse or fail to respond to chemotherapy, as there are no alternative treatments. Therefore, there is an unmet clinical need to develop improved T-ALL therapies. Despite the fact that molecular changes driving T-ALL have been identified, this knowledge has not yet translated into successful therapeutics....